The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study
Abstract
Purpose: Patients with relapsed or refractory chronic lymphocytic leukemia (CLL) have profound immune defects and limited treatment options. Given the dramatic activity of lenalidomide in other B-cell malignancies and its pleotropic immunomodulatory effects, we conducted a phase II trial of this agent in CLL. Patients and Methods: Patients with relapsed or refractory B-cell CLL (B-CLL) were eligible if they required treatment as per the National Cancer Institute Working Group 1996 guidelines. Lenalidomide was administered orally at 25 mg on days 1 through 21 of a 28-day cycle. Response was assessed after each cycle. Patients were to continue treatment until disease progression, unacceptable toxicity, or complete remission. Rituximab was added to lenalidomide on disease progression. Results: Forty-five patients were enrolled, with a median age of 64 years. Sixty-four percent of the patients had Rai stage III or IV disease, and 51% were refractory to fludarabine. The overall response rate was 47%, with 9% of the patients attaining a complete remission. Fatigue, thrombocytopenia, and neutropenia were the most common adverse effects noted in 83%, 78%, and 78% of the patients, respectively. Conclusion: Lenalidomide is clinically active in patients with relapsed or refractory B-CLL. These findings are encouraging and warrant further investigation of this agent in the treatment of this disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical staging of chronic lymphocytic leukemia
Rai, K., Sawitsky, A., Cronkite, E., Chanana, A., Levy, R., & Pasternack, B. (1975) · Blood · doi:10.1182/blood.v46.2.219.219 · Cited by 2,784
Cheson, B., Bennett, J., Grever, M., Kay, N., Keating, M., O'Brien, S., & Rai, K. (1996) · Blood · doi:10.1182/blood.v87.12.4990.bloodjournal87124990 · Cited by 1,819
Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., Marcé, S., López-Guillermo, A., Campo, E., & Montserrat, E. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa023143 · Cited by 1,055
Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia
Rai, K. R., Peterson, B. L., Appelbaum, F. R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G. A., Larson, R. A., Cheson, B. D., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012143432402 · Cited by 1,001
Keating, M. J., O’Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Andreeff, M., Cortes, J., Faderl, S., Thomas, D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.051 · Cited by 950
Efficacy of Lenalidomide in Myelodysplastic Syndromes
List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041668 · Cited by 880
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Byrd, J. C. (2003) · Blood · doi:10.1182/blood-2002-04-1258 · Cited by 571
Wierda, W., O’Brien, S., Wen, S., Faderl, S., Garcia-Manero, G., Thomas, D., Do, K.-A., Cortes, J., Koller, C., Beran, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.516 · Cited by 524
Cited by
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Ramsay, A. G., Johnson, A. J., Lee, A. M., Gorgün, G., Le Dieu, R., Blum, W., Byrd, J. C., & Gribben, J. G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35017 · Cited by 600
Cheson, B. D., Ansell, S., Schwartz, L., Gordon, L. I., Advani, R., Jacene, H. A., Hoos, A., Barrington, S. F., & Armand, P. (2016) · Blood · doi:10.1182/blood-2016-05-718528 · Cited by 521
Dighiero, G., & Hamblin, T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60456-0 · Cited by 366
Ferrajoli, A., Lee, B.-N., Schlette, E. J., O'Brien, S. M., Gao, H., Wen, S., Wierda, W. G., Estrov, Z., Faderl, S., Cohen, E. N., et al. (2008) · Blood · doi:10.1182/blood-2007-12-130120 · Cited by 337
Metadata
- Authors
- Chanan-Khan, A., Miller, K. C., Musial, L., Lawrence, D., Padmanabhan, S., Takeshita, K., Porter, C. W., Goodrich, D. W., Bernstein, Z. P., Wallace, P., Spaner, D., Mohr, A., Byrne, C., Hernandez-Ilizaliturri, F., Chrystal, C., Starostik, P., & Czuczman, M. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-12-01
- Volume
- 24
- Issue
- 34
- Pages
- 5343-5349
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2136242714
- Cited by
- 414
- References
- 29
- FWCI
- 13.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study. https://app.cochat.ai/papers/10.1200/jco.2005.05.0401
- The paper
- Chanan-Khan, A., Miller, K. C., Musial, L., Lawrence, D., Padmanabhan, S., Takeshita, K., Porter, C. W., Goodrich, D. W., Bernstein, Z. P., Wallace, P., Spaner, D., Mohr, A., Byrne, C., Hernandez-Ilizaliturri, F., Chrystal, C., Starostik, P., & Czuczman, M. S. (2006). Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.05.0401
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
